Please assess the completion status of the following clinical trial:

Trial Title: Protocol Calcineurin Inhibitor (CNI) Weaning

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Pre-inclusion criteria :~* Male or female aged between 18 and 80 years (inclusive),~* Having received a deceased donor transplant or living with ABO compatibility,~* First renal allograft for at least 4 years and under 10 years,~* Presenting a stable renal function : serum creatinine with a variation of ± 25% of the average of the year before inclusion,~* Treated with tacrolimus (Prograf®) in combination with MPA (Cellcept® and Myfortic®) + / - steroids (between 5 and 10 mg per day),~* Patient has given informed consent,~* Patient insured,~* Patient (of childbearing age) with effective contraception.~Inclusion Criteria:~* Glomerular Filtration Rate (GFR), defined by the dosage of cystatin C ≥ 40 ml/min/1, 73m²,~* Proteinuria ≤ 0,5 g / day,~* Patient with serum levels of Tacrolimus between 5 to 10 ng / ml on average during the last 6 months (inclusive). It is accepted that 25% of the assays performed during the last 6 months, serum levels of tacrolimus are outside the limits mentioned above (5-10 ng / ml). They must nevertheless be between 3.5 to 12.5 ng / ml (inclusive).~* Patient with serum levels of MPA (Cellcept® and Myfortic®) higher ≥ 30 mg / ml,~* No anti-HLA antibodies at the time of inclusion, verified using highly sensitive techniques (Luminex HD),~* Lack of histological evidence of cellular or humoral acute or chronic or subclinical rejection on renal graft according to the latest classification of Banff 2009.~Exclusion Criteria:~* Patients under age 18 or over 80 years,~* Transplanted from less than 4 years and over 10 years,~* Patients re-transplanted,~* Transplantation of several organs,~* Patient not treated with tacrolimus as maintenance therapy,~* Serum levels of Tacrolimus patient \<5 or \>10 ng / ml,~* Serum levels of MPA of the patient \<30 mg / ml,~* Patients treated with other immunosuppressive drugs that Tacrolimus (Prograf®), MPA (Cellcept® and Myfortic®) and steroids,~* Patient not having a stable graft function at baseline (change in serum creatinine \> 25% of the average of the year before inclusion in the study), with a GFR defined by the dosage of cystatin C \<40 ml/min/1, 73m² at the time of inclusion,- Patients with proteinuria \> 0.5 g at study entry,~* Patient with HLA antibodies at study entry,~* Patient non-compliant,~* Presence of histological evidence of cellular or humoral acute or chronic or subclinical rejection on renal graft according to the latest classification of Banff 2009,~* History of lymphoproliferative disorders,~* Diagnosis of a malignancy within 5 years before enrollment,~* Significantly abnormal hematologic data of a clinical standpoint, as determined by the investigator for hematocrit, hemoglobin, white blood cell count or platelets,~* Data significantly abnormal blood biochemistry of a clinical standpoint, as determined by the investigator,~* Abuse of significant drug or alcohol at the time of inclusion, determined by the investigator,~* Patient positive for antibodies to hepatitis C or hepatitis B surface antigen of hepatitis B (HBsAg) or HIV infection,~* Participation in a clinical study within 3 months,~* Pregnancy, Breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tacrolimus (Type: ACTIVE_COMPARATOR): None
- Withdrawal of Tacrolimus (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).